유바이오로직스

206650KOSDAQ의약품 제조업

63.5 / 100

Reference Date: 2026-06-10

Financial Score24.5 / 40

News Sentiment21.0 / 25

Momentum4.0 / 20

Disclosure14.0 / 15

AI Analysis: ROE significantly exceeds the industry average but PBR raises overvaluation concerns. Plunged 24.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

YuBioLogics, established in 2010, is a biotech company specializing in vaccine development and supply, as well as CRMO services. It supplies cholera vaccines to UNICEF, achieving sales of 65.4 billion KRW in 2023, with continued growth driven by increasing global cholera outbreaks. The company aims to expand its product line to include typhoid and meningitis vaccines, targeting global market leadership.

Number of Employees

397people

Average Salary

60.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

8.25Industry Average 11.936.5Point

Lower than industry avg (good)

PBR

1.95Industry Average 0.890.0Point

2.2x industry avg (risky)

ROE

26.85Industry Average 4.017.0Point

6.7x industry avg (excellent)

Debt Ratio

13.20Industry Average 12.432.0Point

Higher than industry avg (caution)

Trend 2023~20259.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲46.9% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲211.3% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 9.7% (improving, 3yr)

Detailed News Sentiment

9 totalPositive 9Neutral 0Negative 0Average Sentiment Score 83.9

Positive
유바이오로직스, 수막구균 백신 개발 순항…‘제2의 유비콜’ 기대
유바이오로직스의 차세대 백신 개발 성공으로 긍정적인 시장 반응 예상.
Positive
유바이오로직스, 유니세프에 133억원 규모 콜레라 백신 공급
유바이오로직스가 유니세프에 콜레라 백신 공급 계약을 체결하며 국제적 신뢰와 매출 증대 기대를 받고 있다.
Positive
유바이오로직스 출자사 팝바이오텍, 조류독감 백신 개발자금 150억 확....
유바이오로직스의 미국 출자사 팝바이오텍이 CEPI로부터 대규모 연구개발 자금을 확보하여 감염병 백신 개발에 긍정적 영향을 미칠 것으로 예상됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 9,300Won52-week high 16,20052-week low 9,300

1-month return0.0Point

1m -24.39% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

4 totalPositive 2Neutral 2Negative 0

Positive단일판매ㆍ공급계약체결(자율공시)2026-06-05
Neutral기업설명회(IR)개최2026-05-29
Positive단일판매ㆍ공급계약체결(자율공시)2026-05-19
Neutral분기보고서 (2026.03)2026-05-14